What is Monopar Therapeutics's stock issuance proceeds?

Monopar Therapeutics (MNPR) reported stock issuance proceeds of $0 in Q1 2026.

What is the long-term trend for Monopar Therapeutics's stock issuance proceeds?

Over 2 years (2022 to 2025), Monopar Therapeutics's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $109.34K to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Monopar Therapeutics MNPR Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Prime MedicinePRME

$393K—

Wave Life SciencesWVE

$1.93M-21.1%

Perspective TherapeuticsCATX

$290K—

ArriVent BioPharma, Inc.AVBP

$54.72M+740%

Lantheus HoldingsLNTH

$0-100%

PrecigenPGEN

$0+100%

Other financials

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

EPS (diluted)-$0.19—

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation

See full

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monopar Therapeutics's stock issuance proceeds?: Monopar Therapeutics (MNPR) reported stock issuance proceeds of $0 in Q1 2026.
What is the long-term trend for Monopar Therapeutics's stock issuance proceeds?: Over 2 years (2022 to 2025), Monopar Therapeutics's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $109.34K to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.